Multiple-Dose Pharmacokinetics, Safety, and Tolerability of Bosentan, an Endothelin Receptor Antagonist, in Healthy Male Volunteers

Journal of Clinical Pharmacology

Volumn 39, Issue 7, 1999, Pages 703-714

  Weber, Cornelia ^a   Schmitt, Rita ^a   Birnboeck, Herbert ^b   Hopfgartner, Gerard ^b   Eggers, Herwig ^b   Meyer, Joseph ^b   Van Marle, Sjoerd ^c   Viischer, Henk W ^c   Jonkman, Jan H G ^c  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b Preclinical Research   (Switzerland)

^c PRA International USA   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BOSENTAN; ENDOTHELIN RECEPTOR; PYRIMIDINE DERIVATIVE; RO 47 8634; RO 47-8634; RO 48 5033; RO 48-5033; SULFONAMIDE;

AREA UNDER THE CURVE; ARTICLE; BLOOD; BLOOD PRESSURE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG EFFECT; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; MALE; METABOLIC CLEARANCE RATE; METABOLISM; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SYSTOLE;

ADMINISTRATION, ORAL; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; BLOOD PRESSURE; DIASTOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; GASTROINTESTINAL DISEASES; HEADACHE; HUMANS; MALE; METABOLIC CLEARANCE RATE; PYRIMIDINES; RECEPTORS, ENDOTHELIN; SULFONAMIDES; SYSTOLE;

EID: 0033158340     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912709922008344     Document Type: Article

References (20)

1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T: A novel potent vasoconstrictor peptide produced by vascularendothelial cells. Nature 1988;332:411-415.
2. Noll G, Wenzel RR, Luescher TF: Endothelin and endothelin antagonists: potential role in cardiovascular and renal disease. Molecular and Cellular Biochemistry 1996;157:259-267.
3. Webb DJ, Monge JC, Rabelink TJ, Yanagisawa M: Endothelin: new discoveries and rapid progress in clinic. TiPS 1998;19:5-8.
4. Clozel M, Breu V, Gray GA, Kalina B, Löffler B-M, Burri K, Cassal J-M, Hirth G, Müller M, Neidhardt W, Ramuz HJ: Pharmacological characterisation of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. Pharmacol Exp Ther 1994;270:228-235.
5. Kiowski W, Suetsch G, Hunziker P, Muller P, Kim J, Oechslin E, Schmitt R, Jones CR, Bertel O: Evidence of endothelin-1 mediated vasoconstriction in severe chronic heart failure. Lancet 1995;346:732-736.
6. Suetsch G, Kiowski W, Yan X-W, Hunziker P, Christen S, Trobel W, Kim J-H, Rickenbacher P, Bertel O: Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation, 1998;98: 2262-2268.
7. Krum H, Viskoper RJ, Lacourcierge Y, Budde M, Charlon V: The effect of an endothelin receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. New Eng J Med 1998;338:784-790.
8. Williamson DJ, Wallman LL, Jones CR, Keogh AM, Scroope F, Penny R, Weber C, Macdonald PS: Haemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Submitted for publication, Circulation, 1998.
9. Weber C, Schmitt R, Birnboeck H, Hopfgartner G, van Marle SP, Peeters PAM, Jonkman JHG, Jones CR: Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 1996;60:124-137.
10. Ubeaud G, Schmitt C, Jaeck D, Lave T, Coassolo Ph: Bosentan, a new endothelin-receptor antagonist: prediction of the systemic plasma clearance in man from combined in vivo and in vitro data. Xenobiotica 1995;25:1381-1390.
11. Lausecker B, HopfgartnerG: Quantitative analysis of a new endothelin receptor antagonist in human plasma by narrow-bore liquid chromatography and ion spraymass spectrometry. Journal of Chromatography 1995;712:75-83.
12. Eggers H, Goetschi A, Masur S: Determination of the endothelin receptor antagonist bosentan in plasma by HPLC-UV using a combined LLE/SPE procedure for sample purification. Paper presented at HPLC '97, June, Birmingham, UK.
13. Lausecker B, Hess B, Hopfgartner G: Determination of a nonpeptidic endothelin receptor antagonist Ro 47-0203 and its metabolites in different matrices from various species using HPLC ionspray MS/MS. Paper presented at the 46th ASMS Conference on Mass Spectrometry and Allied Topics, May 31-June 4, 1998, Orlando, FL.
14. Benet LZ, Galeazzi RL: Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci 1979;68:1071-1074.
15. Ged C, Rouillon JM, Pichard L, et al: The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J Clin Pharmacol 1989;28:373-387.
16. Ohnhaus EE, Breckenridge AM, Park BK: Urinary excretion of 6β-hydroxycortisol and the time course of measurement of enzyme induction in man. Eur J Clin Pharmacol 1989;36:39-46.
17. Park BK: Assessment of urinary of 6β-hydroxycortisol as an in vivo index of mixed-function oxygenase activity. Br J Clin Pharmacol 1981;12:970102.
18. Holford NN, Ambros RJ, Stoeckel K: Models for describing absorption rate and estimating extent of bioavailability: application to cefetamet pivoxil. J Pharmacokinet Biopharm 1992;20:421-442.
19. Kinirons MT, O'Shea D, Downing TE, Fitzwilliam AT, Joellenbeck L, Groopman JD, Wilkinson GR, Wood AJJ: Absence of correlations among three putative in vivo probes of human cytochrome P450 3A activity in young healthy men. Clin Pharmacol Ther 1993;54:621-629.
20. Ohnhaus EE, Park BK: Measurement of urinary of 6β-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin. Eur J Clin Pharmacol 1979;15:139-145.